Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Immatics Biotechnologies Gmbh patents


Recent patent applications related to Immatics Biotechnologies Gmbh. Immatics Biotechnologies Gmbh is listed as an Agent/Assignee. Note: Immatics Biotechnologies Gmbh may have other listings under different names/spellings. We're not affiliated with Immatics Biotechnologies Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immatics Biotechnologies Gmbh-related inventors


T cell receptors and immune therapy using the same against prame positive cancers

The present invention pertains to antigen recognizing constructs against tumor associated antigens (taa), in particular against preferentially expressed antigen of melanoma (prame). The invention in particular provides novel t cell receptor (tcr) based molecules which are selective and specific for the tumor expressed antigen of the invention. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

08/09/18 / #20180222961

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/26/18 / #20180208641

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/26/18 / #20180208640

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/26/18 / #20180207253

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of gvydgeehsv (seq id no: 303), in which the peptide is in a complex with an mhc molecule.. . ... Immatics Biotechnologies Gmbh

07/26/18 / #20180207252

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

A method of treating a patient who has a cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of gvydgeehsv (seq id no: 303), in which the peptide is in a complex with an mhc molecule.. . ... Immatics Biotechnologies Gmbh

07/26/18 / #20180207251

Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/12/18 / #20180193439

Immunotherapy against melanoma and other cancers

A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has melanoma. ... Immatics Biotechnologies Gmbh

06/14/18 / #20180164315

Novel t cell receptors and immune therapy using the same

The present invention relates to antigen recognizing constructs against a tumor associated antigen (taa) derived from the target protein ddb1 and cul4 associated factor 4-like 2 (dcaf4l2). The invention in particular provides novel t cell receptor (tcr) based molecules which are selective and specific for the taa of the invention. ... Immatics Biotechnologies Gmbh

06/14/18 / #20180162922

T cell receptors with improved pairing

The present invention relates to modified t cell receptor (tcr) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the imgt numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.. . ... Immatics Biotechnologies Gmbh

06/14/18 / #20180161396

Novel t cell receptors and immune therapy using the same

The present invention pertains to antigen recognizing constructs against tumor associated antigens (magea1). The invention in particular provides novel t cell receptor (tcr) based molecules which are selective and specific for the tumor expressed antigen of the invention. ... Immatics Biotechnologies Gmbh

05/24/18 / #20180141993

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

05/17/18 / #20180135039

Method for preparing electrocompetent yeast cells, and method for using said cells

The present invention relates to improved yeast transformation of yeast cells and yeast cell libraries transformed thereby. More specifically, the present invention relates to the transformation of yeast by electroporation.. ... Immatics Biotechnologies Gmbh

05/10/18 / #20180125929

Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. ... Immatics Biotechnologies Gmbh

05/03/18 / #20180117085

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

04/12/18 / #20180100005

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

04/05/18 / #20180094043

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

03/08/18 / #20180066032

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

03/08/18 / #20180064796

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

03/01/18 / #20180055883

Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/22/18 / #20180051080

Novel t cell receptors and immune therapy using the same

The present invention pertains to antigen recognizing constructs against col6a3 antigens. The invention in particular provides novel t cell receptor (tcr) based molecules which are selective and specific for the tumor expressed antigen col6a3. ... Immatics Biotechnologies Gmbh

02/08/18 / #20180037629

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/08/18 / #20180037628

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/08/18 / #20180037627

Novel peptides and combination of peptides for use in immunotherapy against various tumors

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary bladder cancer (ubc), and uterine cancer (uec) includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has hcc, crc, gb, gc, esophageal cancer, nsclc, pc, rcc, bph, pca, oc, melanoma, brca, cll, mcc, sclc, nhl, aml, gbc, ccc, ubc, and/or uec. ... Immatics Biotechnologies Gmbh

02/08/18 / #20180037626

Novel peptides and combination of peptides for use in immunotherapy against various tumors

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary bladder cancer (ubc), and uterine cancer (uec) includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has hcc, crc, gb, gc, esophageal cancer, nsclc, pc, rcc, bph, pca, oc, melanoma, brca, cll, mcc, sclc, nhl, aml, gbc, ccc, ubc, and/or uec. ... Immatics Biotechnologies Gmbh

02/01/18 / #20180030113

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

01/04/18 / #20180000896

Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. ... Immatics Biotechnologies Gmbh

11/30/17 / #20170342125

Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

11/16/17 / #20170326217

Novel immunotherapy against several tumors including neuronal and brain tumors

A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has brain cancer. ... Immatics Biotechnologies Gmbh

11/16/17 / #20170326216

Immunotherapy against melanoma and other cancers

A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has melanoma. ... Immatics Biotechnologies Gmbh

11/16/17 / #20170326215

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

A method of treating a patient who has liver cancer (hcc), breast cancer (brca), melanoma, and/or uterine cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has hcc, brca, melanoma, and/or uterine cancer. ... Immatics Biotechnologies Gmbh

11/09/17 / #20170320913

Immunotherapy against several tumors, such as lung cancer, including nsclc

A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. ... Immatics Biotechnologies Gmbh

11/09/17 / #20170319675

Immunotherapy against several tumors, such as lung cancer, including nsclc

A method of treating a patient who has non-small cell lung carcinoma (nsclc), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has nsclc, lung cancer, gastric cancer, and/or glioblastoma. ... Immatics Biotechnologies Gmbh

10/26/17 / #20170305993

Novel peptides and combination of peptides for use in immunotherapy against various tumors

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary bladder cancer (ubc), and uterine cancer (uec) includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has hcc, crc, gb, gc, esophageal cancer, nsclc, pc, rcc, bph, pca, oc, melanoma, brca, cll, mcc, sclc, nhl, aml, gbc, ccc, ubc, and/or uec. ... Immatics Biotechnologies Gmbh

10/26/17 / #20170305992

Novel peptides and combination of peptides for use in immunotherapy against various tumors

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary bladder cancer (ubc), and uterine cancer (uec) includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has hcc, crc, gb, gc, esophageal cancer, nsclc, pc, rcc, bph, pca, oc, melanoma, brca, cll, mcc, sclc, nhl, aml, gbc, ccc, ubc, and/or uec. ... Immatics Biotechnologies Gmbh

10/26/17 / #20170305991

Immunotherapy against melanoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

10/26/17 / #20170305982

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has prostate cancer. ... Immatics Biotechnologies Gmbh

10/26/17 / #20170304399

Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

A pharmaceutical composition contains an antibody or a fragment thereof specific for col6a3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. ... Immatics Biotechnologies Gmbh

10/12/17 / #20170290897

Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against aml and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

09/21/17 / #20170267738

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Disclosed are t-cell receptors (tcrs) binding to tumor-associated antigens (taas) for targeting cancer cells, t-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are tcrs and their variants that bind to hla class i or ii molecules with a peptide, such as mag-003 have the amino acid sequence of kvlehvvrv (seq id no:1). ... Immatics Biotechnologies Gmbh

09/21/17 / #20170266271

Peptides and combination of peptides for use in immunotherapy against cancers

The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

09/14/17 / #20170260249

Uterine cancer treatments

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

09/07/17 / #20170253633

Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/20/17 / #20170202937

Novel immunotherapy against several tumors, such as lung cancer, including nsclc

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189513

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189512

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189511

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189510

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189509

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189508

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189507

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189506

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189505

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

07/06/17 / #20170189504

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

06/22/17 / #20170173132

Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

06/22/17 / #20170173131

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

06/15/17 / #20170165340

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

06/15/17 / #20170165339

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

06/15/17 / #20170165338

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

06/15/17 / #20170165337

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

06/15/17 / #20170165335

Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

06/08/17 / #20170158750

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

05/18/17 / #20170136108

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

04/13/17 / #20170101473

Anti-wt1/hla-specific antibodies

The present invention relates to antibodies or fragments thereof binding to human wt1/hla. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.. ... Immatics Biotechnologies Gmbh

04/06/17 / #20170096461

Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

03/23/17 / #20170080070

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

03/02/17 / #20170056488

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

03/02/17 / #20170056487

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

03/02/17 / #20170056486

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037111

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037110

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037107

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037098

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037097

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037096

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037095

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037094

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037093

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170037092

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/09/17 / #20170035807

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

02/02/17 / #20170029486

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh

01/26/17 / #20170022251

Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. ... Immatics Biotechnologies Gmbh

01/05/17 / #20170002055

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. ... Immatics Biotechnologies Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immatics Biotechnologies Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immatics Biotechnologies Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###